About Us
Overview
Leadership Team
Milestones
Science & Pipeline
RNAi Mechanism
RNAi Therapeutics
Pipeline
Investors & Partners
Investors
Partners
Careers
Who Are We
Our Culture
Job Opportunities
News
Press Releases
Contact Us
CN
EN
About Us
Overview
Leadership Team
Milestones
Science & Pipeline
RNAi Mechanism
RNAi Therapeutics
Pipeline
Investors & Partners
Investors
Partners
Careers
Who Are We
Our Culture
Job Opportunities
News
Press Releases
Contact Us
CN
EN
News
Explore and Witness SanegeneBio' s Innovative Footprints
Press Releases
Press Releases
2025
2024
2023
Mar. 07, 2025
SanegeneBio announces the initiation of phase II clinical trials for the siRNA drug SGB-9768 targeting C3
More
Prev
1
Next
Prev
1/1
Next
About Us
Overview
Leadership Team
Milestones
Science & Pipeline
RNAi Mechanism
RNAi Therapeutics
Pipeline
Careers
Who Are We
Our Culture
Job Opportunities
News
Press Releases
Contact Us
Terms of use
|
Privacy Policy
Copyright © 2024 Suzhou Sanegene Bio Inc. All rights reserved
Home
Phone
Top
